Lilly Hunkers Down Through Sales Declines, Shies Away From M&A
This article was originally published in The Pink Sheet Daily
Executive Summary
The Indianapolis drug maker is putting forth a brave face as it trudges through earnings declines due to patent losses, and isn’t planning any large-scale M&A transactions to fight its way through to more profitable days.